Federico Caligaris‐cappio
#159,398
Most Influential Person Now
Federico Caligaris‐cappio's AcademicInfluence.com Rankings
Federico Caligaris‐cappiophilosophy Degrees
Philosophy
#9141
World Rank
#12656
Historical Rank
Logic
#6133
World Rank
#7617
Historical Rank
Download Badge
Philosophy
Why Is Federico Caligaris‐cappio Influential?
(Suggest an Edit or Addition)Federico Caligaris‐cappio's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. (2008) (3147)
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (2010) (1805)
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (2014) (1363)
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. (2018) (874)
- The microenvironment in mature B-cell malignancies: a target for new treatment strategies. (2009) (571)
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial (2009) (547)
- Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. (2006) (540)
- Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia (1982) (471)
- B-cell chronic lymphocytic leukemia: a bird of a different feather. (1999) (445)
- Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. (2001) (403)
- Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. (2007) (358)
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia (2007) (352)
- Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 (2002) (283)
- The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. (2003) (278)
- MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. (1999) (277)
- Chronic lymphocytic leukemia: revelations from the B-cell receptor. (2004) (265)
- Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. (2008) (241)
- Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. (2004) (235)
- RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS (2014) (235)
- Role of the microenvironment in chronic lymphocytic leukaemia (2003) (234)
- Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. (2005) (233)
- B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. (1996) (227)
- Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. (1992) (213)
- Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? (2008) (206)
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL (2017) (205)
- ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). (2013) (194)
- Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. (2005) (183)
- Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma (1989) (171)
- Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. (1985) (166)
- CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. (2003) (158)
- Respiratory function in systemic lupus erythematosus: relation with activity and severity (1996) (157)
- Vδ1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid (2004) (156)
- CD30 and type 2 T helper (Th2) responses (1995) (155)
- Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. (1989) (144)
- General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. (2011) (143)
- The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. (2009) (137)
- Expression and function of toll like receptors in chronic lymphocytic leukaemia cells (2009) (136)
- 'Role of bone marrow stromal cells in the growth of human multiple myeloma. (1991) (136)
- The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. (2000) (125)
- Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. (1995) (122)
- An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. (1999) (119)
- Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies (1983) (114)
- MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. (2010) (113)
- Role of bone marrow stromal cells in the growth of human multiple myeloma. (1991) (113)
- Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. (1984) (113)
- Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. (2010) (108)
- Chronic B cell malignancies and bone marrow microenvironment. (2002) (107)
- Biology of chronic lymphocytic leukemia. (2000) (104)
- Surface markers in chronic lymphoid leukemias of B cell type. (1985) (103)
- Cytokines involved in the progression of multiple myeloma (1993) (98)
- Anemia of chronic disorders in systemic autoimmune diseases. (1997) (98)
- Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia and hairy cell leukemia. (1986) (97)
- Age‐dependent accumulation of monoclonal CD4+CD8+double positive T lymphocytes in the peripheral blood of the elderly (2007) (92)
- Differential effects on CLL cell survival exerted by different microenvironmental elements. (2005) (91)
- Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. (2004) (90)
- HS1 has a central role in the trafficking and homing of leukemic B cells. (2010) (89)
- Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era (2015) (86)
- Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. (1995) (86)
- In leukaemic CD5+ B cells the expression of BCL‐2 gene family is shifted toward protection from apoptosis (1996) (86)
- High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. (2015) (84)
- How the microenvironment wires the natural history of chronic lymphocytic leukemia. (2014) (82)
- Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. (2016) (82)
- Primary lymphoma of the heart. A case report and review of the literature. (2002) (81)
- Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised , open-label , phase 3 trial (2010) (80)
- Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients (2010) (80)
- HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. (2005) (79)
- ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage (2006) (78)
- Targeting B-cell anergy in chronic lymphocytic leukemia. (2012) (78)
- Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B‐cell chronic lymphocytic leukemia (1985) (76)
- Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. (1985) (75)
- Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy (2013) (75)
- Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes (1988) (73)
- A novel Rag2-/-gammac-/--xenograft model of human CLL. (2010) (72)
- Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. (2007) (71)
- Human normal CD5+ B lymphocytes can be induced to differentiate to CD5- B lymphocytes with germinal center cell features. (1989) (71)
- High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders (1996) (71)
- An erythroid specific nuclear factor binding to the proximal CACCC box of the beta-globin gene promoter. (1988) (68)
- Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors (2012) (68)
- CXCL13 (BCA‐1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells (2002) (67)
- Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R‐IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high‐dose methotrexate‐based chemotherapy (2013) (67)
- The nature of the B lymphocyte in B-chronic lymphocytic leukemia. (1993) (66)
- Bortezomib induces autophagic death in proliferating human endothelial cells. (2010) (65)
- From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. (2007) (62)
- Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA. (1984) (60)
- MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated γδ Lymphocytes (2005) (59)
- Integrin distribution and cytoskeleton organization in normal and malignant monocytes. (1990) (59)
- Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib (2008) (58)
- Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. (2017) (55)
- Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. (2012) (55)
- Monoclonal B-cell lymphocytosis: right track or red herring? (2012) (55)
- Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. (2011) (55)
- Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. (2010) (55)
- Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. (1997) (52)
- Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses1 (2004) (52)
- Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. (2010) (51)
- Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division (2008) (51)
- Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. (1988) (50)
- The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy (1998) (49)
- Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. (2015) (49)
- Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors (2011) (47)
- Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia. (1994) (46)
- HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. (2016) (46)
- HLA-Dr+ T cells of the Leu 3 (helper) type infiltrate the kidneys of patients with systemic lupus erythematosus. (1985) (46)
- Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. (1984) (45)
- Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. (2011) (44)
- Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia (2019) (43)
- Bone marrow microenvironment and the progression of multiple myeloma. (1992) (42)
- Circulating ‘trophoblast’ cells in pregnancy have maternal genetic markers (1988) (41)
- Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. (2010) (41)
- The origin of B-cell chronic lymphocytic leukemia. (2006) (41)
- MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. (2005) (41)
- ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor (2007) (41)
- Characterization of bone marrow stromal cells from multiple myeloma. (1994) (40)
- Molecular investigation of the cytokines produced by normal and malignant B lymphocytes. (1992) (40)
- Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions (2013) (40)
- The role of Toll-like receptors in chronic B cell malignancies (2009) (40)
- In vitro growth of human multiple myeloma: implications for biology and therapy. (1992) (38)
- The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. (1993) (37)
- In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors (2012) (37)
- Murine monoclonal antibodies as probes for the phenotypical, functional, and molecular analysis of a discrete peripheral blood lymphocyte population exerting natural killer activity in vitro. (1985) (35)
- Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies. (1987) (35)
- An overview of chronic lymphocytic leukaemia biology. (2010) (34)
- Chronic lymphocytic leukemia. (2007) (33)
- Idiopathic Neutropenia with Normocellular Bone Marrow: an Immune‐Complex Disease (1979) (33)
- Defective apoptosis due to Bcl-2 overexpression may explain why B-CLL cells accumulate in G0. (1995) (33)
- The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. (2003) (32)
- The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia (2011) (32)
- The normal counterpart to the chronic lymphocytic leukemia B cell. (2007) (31)
- Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (31)
- B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia (2016) (31)
- Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment (2018) (31)
- Generation and characterization of murine monoclonal antibodies against HLA Class II molecules. (1984) (30)
- Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia (2019) (29)
- Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia (2016) (29)
- HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells (2007) (29)
- Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma (2010) (29)
- Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation (2008) (25)
- Cell-cell and cell-matrix adhesion structures may influence the growth pattern of chronic lymphoid malignancies. (1989) (25)
- What is the CLL B-lymphocyte? (1996) (25)
- Inflammation, the microenvironment and chronic lymphocytic leukemia (2011) (25)
- Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL (2010) (24)
- Fludarabine ability to down‐regulate Bcl‐2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations (1997) (24)
- Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension (1998) (23)
- Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation (2015) (21)
- Toll-like Receptors in Chronic Lymphocytic Leukemia (2012) (21)
- CD38 modifications in chronic lymphocytic leukemia: are they relevant? (2004) (21)
- Interleukin-2 enhances the production of tumor necrosis factor-alpha in activated B-type chronic lymphocytic leukemia (B-CLL) cells. (1993) (20)
- Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. (2016) (20)
- CDS and CD21 molecules are a functional unit in the cell/substrate adhesion of B‐chronic lymphocytic leukemia cells (1988) (19)
- Na+/H+ antiporter has different properties in human B lymphocytes according to CD5 expression and malignant phenotype (1991) (18)
- B‐chronic lymphocytic leukaemia patients with stable benign disease show a distinctive membrane phenotype (1984) (18)
- A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression (2018) (17)
- Relationship between autoimmunity and immunodeficiency in CLL. (1997) (17)
- Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma. (1995) (17)
- A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? (2011) (17)
- B cells and their fate in health and disease. (1996) (17)
- How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection (2010) (16)
- The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia (2011) (15)
- Safety and activity of a new intensive short‐term chemoimmunotherapy in HIV‐positive patients with Burkitt lymphoma (2012) (15)
- The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model. (2004) (15)
- Autoimmunity, autoimmune diseases and lymphoproliferative disorders. (1994) (15)
- How immunology is reshaping clinical disciplines: the example of haematology (2001) (14)
- Soluble CD30 in primary Sjögren's syndrome. (1999) (13)
- Pathogen‐specific B‐cell receptors drive chronic lymphocytic leukemia by light‐chain‐dependent cross‐reaction with autoantigens (2017) (13)
- The immunoglobulin gene repertoire of low-count CLL-like MBL is different from CLL: diagnostic implications for clinical monitoring (2008) (12)
- Institute-Working Group (NCI-WG) 1996 guidelines Lymphocytic Leukemia (IWCLL) updating the National Cancer leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (12)
- Hyaline-vascular type of Castleman's disease (angiofollicular lymph node hyperplasia) with monotypic plasma cells. An immunohistochemical study with monoclonal antibodies. (1987) (11)
- Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study (2013) (10)
- Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia (2014) (10)
- Chronic Lymphocytic Leukemia: “Cinderella” Is Becoming a Star (2009) (10)
- Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas. (2002) (10)
- C3b receptors mediate the growth factor-induced proliferation of malignant B-chronic lymphocytic leukemia lymphocytes. (1987) (9)
- Definition by CB12 monoclonal antibody of a differentiation marker specific for human monocytes and their bone marrow precursors. (1986) (9)
- Cellular interactions, immunodeficiency and autoimmunity in CLL. (2000) (9)
- Autoimmune phenomena and hepatitis C virus in lymphoproliferative and connective tissue disorders. (1997) (9)
- International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. (2004) (9)
- BCL-2 in B-chronic lymphocytic leukemia. (1992) (8)
- Analysis of T-cell clones in systemic lupus erythematosus. (2000) (8)
- Human B cell populations (1997) (8)
- Autoimmune disorders and lymphoma. (2008) (8)
- Correction: Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy (2013) (8)
- Phenotypic, cytogenetic and molecular characterization of a new B-chronic lymphocytic leukaemia (B-CLL) cell line. (1987) (8)
- Immunotherapy in lymphoma (2017) (8)
- Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line (2015) (8)
- A possible pathogenetic role of cationic proteins (CP) released by stored granulocytes in the development of pulmonary infiltrates after granulocyte transfusions. (2009) (7)
- The Immunoglobulin Gene Repertoire of Low-Count CLL-Like MBL Is Different from CLL: Diagnostic Considerations and Implications for Clinical Monitoring (2008) (7)
- Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models (2016) (7)
- Lentiviral transduction of primary myeloma cells with CD80 and CD154 generates antimyeloma effector T cells. (2005) (7)
- SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders (2014) (7)
- Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors (2011) (7)
- IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development (2019) (7)
- Cyclosporin A in the treatment of B-chronic lymphocytic leukemia (B-CLL) (1994) (7)
- Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen. (1984) (6)
- Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia (2022) (6)
- Alternative splicing of CD79a (Ig alpha) and CD79b (Ig beta) transcripts in human B-CLL cells. (1999) (6)
- Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). (2011) (6)
- On the role of endogenously produced TNF-alpha and IL-6 as regulators of growth and differentiation of B-type chronic lymphocytic leukemia cells in vitro. (1992) (6)
- Group 1996 guidelines Working - Lymphocytic Leukemia updating the National Cancer Institute leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (5)
- Anergy: the CLL cell limbo. (2014) (5)
- CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL (2010) (5)
- What are we learning from familial chronic lymphocytic leukemia? (2002) (5)
- Differential Functional Outcomes After Stimulation Via Innate Immunity Receptors In Chronic Lymphocytic Leukemia Subtypes Defined by the Molecular Features of the Immunoglobulin Receptor (2010) (5)
- Circulating malignant precursors in monoclonal gammopathies (1989) (5)
- From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia. (2014) (4)
- European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986. (1987) (4)
- Comparative analysis of normal and malignant CD5+ B lymphocytes. (1988) (4)
- NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) . (2011) (4)
- Where is the biology of CLL leading us? (2010) (4)
- Rearrangement for the T‐cell receptor gene and co‐expression of immature T‐cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia (1987) (4)
- Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) (2012) (3)
- B cell populations: the multiple myeloma model. (1997) (3)
- A novel pathway of human B cell activation initiated by CK226 surface antigen (1990) (3)
- A novel gene for an old disease (2006) (3)
- Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM). (2009) (3)
- NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study (2008) (3)
- In Vitro Studies Provide Evidence that Multiple Paracrine Loops may be Operating in Multiple Myeloma (1991) (3)
- Functional and molecular characterization by the CB04 monoclonal antibody of a cell surface structure exerting C3-complement receptor activity (1985) (3)
- DUO: a phase 3 trial of the PL3K-delta,gamma inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphorytic lymphoma (2014) (3)
- Human B Cell Populations (Preliminary Pages) (1997) (3)
- ROMA illuminates CLL genomic lesions. (2009) (3)
- Respiratory symptoms, lung function tests, airway responsiveness, and bronchoalveolar lymphocyte subsets in B-Chronic lymphocytic leukemia (2011) (3)
- The origin of B-chronic lymphocytic leukaemia (B-CLL) and its relationship to hairy cell leukaemia (HCL). (1985) (3)
- Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens. (2009) (3)
- A novel rag2 -/- γ c-/- -xenograft model of human CLL (2009) (3)
- Analysis by Monoclonal Antibodies of Cell Surface Structures Marking Discrete Steps of Cell Differentiation (1985) (2)
- Cyclophosphamide/cyclosporin-A treatment of multicentric Castleman's disease with Kaposi's sarcoma. (2000) (2)
- Chronic lymphocytic leukemia : revelations from the B-cell receptor Running title : The B-cell receptor in CLL (2004) (2)
- Chronic lymphocytic leukemia (CLL): a model for understanding and treating chronic B-cell malignancies. (2013) (2)
- The cycling history of CLL (2004) (2)
- Interferons in the treatment of multiple myeloma. (1990) (2)
- A Molecular Signature of Anergy Detected in a Subset of CLL Patients. (2007) (2)
- Membrane-microfilament interactions in the cells of B-chronic lymphocytic leukemia. (1987) (2)
- INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (2014) (2)
- Biology of the malignant plasma cell (2004) (2)
- IG genes and hairy cell leukemia. (2009) (1)
- RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL (2014) (1)
- High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial (2014) (1)
- Novel Mouse Models of Chronic Lymphocytic Leukemia (CLL) Unravel the Molecular Mechanisms Controlling Bone Marrow Involvement by Leukemic B Cells. (2009) (1)
- -xenograft model of human CLL (2010) (1)
- Interrelationships of cell-substrate and cell-cell adhesion structures in B-chronic lymphocytic leukemia (B-CLL) cells. (1988) (1)
- lymphocytic leukemia and hairy cell leukemia (2005) (1)
- The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma (2012) (1)
- A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC) (2008) (1)
- XVI International Workshop on Chronic Lymphocytic Leukemia 2015 6–9 September 2015 Sydney, Australia (2015) (1)
- Bertilaccio MT, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood. 2011;118(3):660–669. (2012) (1)
- Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary (1998) (1)
- Hepatitis C virus and lymphoid malignancies. (2003) (1)
- New trends in the biology of B-chronic lymphocytic leukemia. (1986) (1)
- Defining response criteria in CLL patients treated in clinical research trials Response (2010) (1)
- Nitric oxide in systemic sclerosis lung: controversies and expectations. (1998) (1)
- Directing CLL-cell traffic. (2015) (1)
- Anergy in CLL: Moving Towards the Clinic (2014) (1)
- Dissecting the natural history of chronic lymphocytic leukemia to discover new therapeutic targets (2009) (1)
- Combining CD23 chimeric antigen receptor immunotherapy and lenalidomide as a novel therapeutic strategy for chronic lymphocytic leukemia (2014) (1)
- Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results. (2011) (1)
- Development of B cell subpopulations in humans and its relevance to malignancy. (1985) (1)
- CLL patients: a molecular signature of anergy Constitutive activation of distinct BCR-signaling pathways in a subset of (2013) (1)
- Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors. (2009) (1)
- IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment (2015) (1)
- Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al (2009) (1)
- [Cellular and molecular mechanisms conditioning the accumulation of resting neoplastic cells in B-lymphocyte chronic lymphatic leukemia]. (1991) (0)
- myeloma 'Role of bone marrow stromal cells in the growth of human multiple (2011) (0)
- 2.3 HS1 Protein Defines a Distinct Signaling Pathway and Influences the Cell Homing and Migratory Capacity in CLL Primary Cells (2011) (0)
- Abstract 1023: Duration of signaling through IgM and IgD receptors differentially influences cell survival and BCL6-regulated CCL3/4 chemokine production in Chronic Lymphocytic Leukemia (CLL) (2015) (0)
- Lymphocytes Can Be Induced to Differentiate to CD 5 B Lymphocytes With Germinal Center Cell Features (2005) (0)
- Mature Dendritic Cells That Efficiently Differentiate into Functionally Competent Leukemia-Derived Immature Dendritic Cells (2004) (0)
- Chronic Lymphocytic Leukemia and the B-Cell Receptor (2008) (0)
- Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo (2013) (0)
- Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia (2013) (0)
- It is recommended that you download this PDF to your computer for furture reference. It spells out how CLL is treated clinically. (2008) (0)
- Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL (2012) (0)
- Phenotypic and functional characterization of cell surface structures involved in natural killing (1988) (0)
- Management of Non-Hodgkin’s Lymphomas: Conclusions of the First Intercity Meeting, 1986 (1990) (0)
- Erratum: The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia (Leukemia (2011) 25 (1760-1767) doi: 10.1038/leu.2011.149) (2011) (0)
- A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression (2018) (0)
- 8CL-2 in 8-Chronic Lymphocytic Leukemia (1992) (0)
- CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism (2019) (0)
- Cancer Therapy : Preclinical In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors (2013) (0)
- Chronic lymphocytic leukemia (CLL) : a model for understanding and treating chronic B-cell malignancies (第75回日本血液学会学術集会 教育講演特集号) -- (リンパ系腫瘍 : ALL/ML) (2013) (0)
- LPR mice with Toll-IL-1 Receptor 8 deficiency are prone to develop B-cell lymphomas (2014) (0)
- apoptosis in B-cell chronic lymphocytic leukemia Survivin is expressed on CD40 stimulation and interfaces proliferation and (2013) (0)
- Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts) with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A multicenter phase II trial. (2014) (0)
- Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome (2014) (0)
- LYMPHOID NEOPLASIA HIF-1 a regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment (2016) (0)
- normal and leukemic CD5+ B lymphocytes CD100/Plexin-B1 interactions sustain proliferation and survival of (2013) (0)
- [New perspectives in immuno-mediated blood diseases]. (2002) (0)
- Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM) (2008) (0)
- in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene Geographic patterns and pathogenetic implications of IGHV gene usage (2013) (0)
- ToixattractingchemokinIsakeproducedbycllbcells, after CD40 stimulation (2000) (0)
- Are we getting closer to understanding the pathogenesis of chronic lymphocytic leukemia (2009) (0)
- Leukemic Dendritic Cells Expand Central Memory T Lymphocytes From HCT Donors Able to React against the Original Leukemia in Vitro and In Vivo. (2009) (0)
- Chronic lymphocytic leukemia: an enigma for both the clinician and the immunologist (2007) (0)
- lymphocytic leukemia and hairy cell leukemia Cytoskeleton organization is aberrantly rearranged in the cells of B chronic (2011) (0)
- Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC). (2010) (0)
- chronic lymphocytic leukemia Perspectives on the use of new diagnostic tools in the treatment of (2013) (0)
- Predictive potential of angiogenic plasma biomarkers (PBs) in phase I trial with NGR-hTNF. (2010) (0)
- from CLL: diagnostic implications for clinical monitoring The immunoglobulin gene repertoire of low-count CLL-like MBL is different (2011) (0)
- Apoptosis and the treatment of chronic lymphoid malignancies: the B-chronic lymphocytic leukemia (B-CLL) model (1995) (0)
- Monocyte/Macrophage Lineage Cells Significantly Influence The Survival And Proliferation Of Chronic Lymphocytic Leukemia (Cll) Cells (2014) (0)
- Bone marrow microenvironment and malignant B cells in human multiple myeloma (1994) (0)
- The multiple myeloma model. (1997) (0)
- A frequent EcoRI polymorphism in the bcl-2 gene (1993) (0)
- malignant B lymphocytes Vinculin, talin, and integrins are localized at specific adhesion sites of (2011) (0)
- Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line (2015) (0)
- Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC). (2016) (0)
This paper list is powered by the following services:
